ClinicalTrials.gg
SuspendedNCT05138458IMAGINEUpdated Nov 13, 2023

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

A Phase 1/2 interventional study of MT-101 and MT-101 + Conditioning (Lymphodepleting) Chemotherapy in Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous and Mycosis Fungoides, sponsored by Myeloid Therapeutics. Suspended at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Myeloid Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

Why this study was suspended
Temporary operational pause; no safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States — 21 open to participants now, 28 under way, 2 of them phase 3. Lymphoma, T-Cell, Peripheral · United States.

Planned enrollment
74th of 157
40 · median 36
Started
2021
with 4 others
Phase 1/2
24 of 164
3 open now
Registered
136th of 164
by date

Among the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, this one is the 74th largest by planned enrollment of the 157 interventional ones that give a count, is one of 5 that started in 2021, is one of 24 in phase 1/2, and was the 136th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

21 of the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.

Read the detailed description

The research study is divided into two parts. The first part will be to determine the safety and tolerability of the study drug product. During this part of the study, there will be 4 groups of study patients. The first group of patients will receive a low dose of cells, the second group will receive the low dose of cells and lymphodepleting chemotherapy to reduce the number of T cells in the blood, the third group will receive a higher dose of cells, and the fourth group will receive the higher dose of cells and lymphodepleting chemotherapy to reduce the number of T cells in the blood. In the second part of the study, cells with or without chemotherapy will be administered based on results of Part 1 and the safety, tolerability, and efficacy of MT-101 will be assessed. All patient groups will receive 6 doses of drug product over 3 weeks.

03

Conditions studied

  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides
  • Adoptive Cellular Immunotherapy
  • Cell Therapy

Keywords

  • T Cell Lymphoma
  • PTCL
  • CTCL
  • MF
  • MT-101
  • CD5 chimeric antigen receptor
  • Myeloid cells
  • Monocytes
  • Chimeric Antigen Receptor
  • CAR Monocyte Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults age > or equal to18 at the time the is signed
  • or relapsed confirmed T Cell Lymphoma (TCL): Peripheral T cell Lymphoma not otherwise specified (PTCL-NOS) , Angioimmunoblastic T cell Lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALCL), ALK-positive ALCL, or Mycosis Fungoides (MF) stage IIB-IV including large cell transformation
  • CD5-expressing tumor by IHC or flow cytometry of tumor within 3 months of Screening or at Screening
  • performance status \< 2
  • Adequate organ function as defined in the protocol.

Key Exclusion Criteria:

  • B1 and B2 disease (as defined in protocol for subjects with MF)
  • Known central nervous system involvement by PTCL
  • History of transplant
  • History of intolerance to leukapheresis, plasmapheresis, or blood donation
  • Pregnant or nursing women
  • Any acute illness including fever (> 100.4°F or > 38°C), except fever related to tumor
  • Active systemic bacterial, fungal, or viral infection
  • Active chronic infection
  • Other primary , except adequately treated malignancies or complete remission
  • Active disease that has required systemic therapy in the last 2 years
  • History of hemophagocytic lymphohistiocytosis
  • History of severe, immediate reaction attributed to penicillin
  • Any other condition that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1 and Cohort 3

    MT-101

    Biological: MT-101

  • Experimental
    Cohort 2 and Cohort 4

    MT-101 preceded by conditioning (lymphodepleting) chemotherapy

    Other: MT-101 + Conditioning (Lymphodepleting) Chemotherapy

Interventions

  • BiologicalMT-101

    CD5 ATAK cells

  • OtherMT-101 + Conditioning (Lymphodepleting) Chemotherapy

    IV administration of fludarabine and cyclophosphamide

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of MT-101

    Safety and tolerability of the drug will be determined based on observed adverse events (AEs), including all potential dose limiting toxicities.

    Time frame: 4 weeks

Secondary outcomes

  1. MT-101 cell kinetics in blood

    The quantity of MT-101 RNA in the blood.

    Time frame: 4 weeks

  2. The objective response rate

    The ORR is defined as the number (%) of subjects achieving a best overall response of complete response (CR) or partial response (PR)

    Time frame: 24 weeks

Other outcomes

  1. Duration of response (DOR)

    DOR is the time interval between the date of first assessment of PR or CR to the date of the follow-on first documentation of progressive disease or death, whichever occurs earlier.

    Time frame: 48 weeks

  2. Progression free survival (PFS)

    PFS is defined as the time from the date of the first administration of MT-101 to the date of first documentation of progressive disease or death, whichever occurs earlier.

    Time frame: 48 weeks

  3. Overall survival (OS)

    OS is defined as the time from date of the first administration of MT-101 to the date of death.

    Time frame: 48 weeks

07

Study locations

6 sites
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Dana-Farber/Mass General Brigham Cancer Care
    Boston, Massachusetts 02215, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Virginia Comprehensive Cancer Center
    Charlottesville, Virginia 22908, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Nov 2024, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2021
First posted
Dec 1, 2021
StartActual
Dec 15, 2021
Primary completionEst.
Nov 2024
CompletionEst.
Oct 2025
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05138458
Lead sponsor
Myeloid Therapeutics
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Dec 15, 2021
Primary completion
Nov 2024 (estimated)
Completion
Oct 2025 (estimated)
Last update
Nov 13, 2023

Study contacts

Michele Gerber, MD, MPH
study director · Myeloid Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion